SCHEMBL13790071

SCHEMBL13790071

NNC(=O)c1cc2c3c(c1)CCC3CCC2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.40
LMNA P02545 4/20 0.40
GAA P10253 3/20 0.40
MAPT P10636 3/20 0.40
HTT P42858 2/20 0.40
KDM4E B2RXH2 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
NSD2 O96028 1/20 0.40
ALPL P05186 1/20 0.40
POLB P06746 1/20 0.40
ALPI P09923 1/20 0.40
ALPG P10696 1/20 0.40
APEX1 P27695 1/20 0.40
RECQL P46063 1/20 0.40
BLM P54132 1/20 0.40
CASP6 P55212 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
MEN1 O00255 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13790034 0.80 ALDH1A1 (0.46) ALDH1A1MAPTHTTKDM4EPOLB
SCHEMBL13790186 0.79 ALDH1A1 (0.41) ALDH1A1LMNAMAPTHTTTDP1
SCHEMBL828937 0.76 ALDH1A1 (0.48) ALDH1A1LMNAMAPTHTTKDM4E
SCHEMBL829031 0.75 ALDH1A1 (0.43) ALDH1A1LMNAMAPTHTTTDP1
SCHEMBL2394763 0.73 MEN1 (0.54) ALDH1A1GAAHTTMEN1CYP1A2
SCHEMBL830332 0.71 KMO (0.49) ALDH1A1MAPTHTTKDM4EL3MBTL1
SCHEMBL829038 0.70 NPC1 (0.42) ALDH1A1LMNAMAPTTDP1MEN1
SCHEMBL2396155 0.70 PTPN1 (0.51) ALDH1A1MAPTMEN1CYP1A2CYP2C19
SCHEMBL2398284 0.69 RNASEH1 (0.41) ALDH1A1GAAMAPTHTTNPC1
SCHEMBL2393053 0.69 MEN1 (0.52) ALDH1A1GAAMAPTHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170830-A1 Tricyclic Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease MERCK SHARP & DOHME CORP. 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170830-A1 Tricyclic Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease BACE1, BACE2, PSEN1 ALDH1A1 2151/4885LMNA 812/4885GAA 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.